Can a daily regimen of 150 mg Imuran (azathioprine) and a low-dose steroid (5 mg daily) for 8 months affect blood markers, including liver function tests, Complete Blood Count (CBC), and inflammatory markers, such as C-Reactive Protein (CRP) and Red Cell Distribution Width (RDW)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Azathioprine and Low-Dose Steroids Affect Blood Markers?

Yes, both azathioprine 150 mg daily and prednisone 5 mg daily can significantly affect multiple blood markers, including liver function tests, complete blood count parameters, and inflammatory markers like CRP and RDW.

Effects on Liver Function Tests

Azathioprine causes hepatotoxicity in a dose-dependent manner, with elevation of serum alkaline phosphatase, bilirubin, and transaminases being well-documented complications. 1

  • Hepatotoxicity occurs in less than 1% of patients with inflammatory conditions but is more common (up to 6 months post-treatment) in transplant recipients 1
  • Periodic measurement of serum transaminases, alkaline phosphatase, and bilirubin is mandatory for early detection of hepatotoxicity 2, 1
  • Azathioprine can cause severe hepatic complications including cirrhosis and nodular regenerative hyperplasia, even after years of therapy 3, 4, 5
  • The dose of azathioprine should be reduced or stopped if liver enzymes exceed three times the upper limit of normal 2

Effects on Complete Blood Count

Myelosuppression is the most clinically significant hematologic effect, occurring in over 50% of transplant patients and 28% of rheumatoid arthritis patients to some degree. 1

Leukopenia

  • Leukopenia (WBC <3.0 × 10⁹/L) occurs in 3.8% of patients, with severe leukopenia (WBC <2.0 × 10⁹/L) in approximately 1.2% 6
  • Azathioprine should be stopped or reduced by 50% immediately if WBC falls below 4,000/mm³ 2
  • Myelotoxicity can develop at any time during treatment, from 2 weeks to 11 years after initiation 6

Thrombocytopenia

  • Thrombocytopenia (platelets <100,000 × 10⁶/L) occurs in 2% of patients 6
  • Immediate withdrawal and hematology consultation are required when platelets drop below 50 × 10⁹/L 7

Macrocytosis and Anemia

  • Macrocytic anemia is a common finding that can be used to assess patient compliance 8
  • Anemia occurs but is less common than leukopenia 8

Lymphopenia

  • Lymphopenia occurs in 57% of patients on long-term azathioprine maintenance therapy 2
  • Azathioprine discontinuation or dose reduction is recommended when lymphocyte count falls below 0.5 × 10⁹/L 7

Effects on Inflammatory Markers

Low-dose corticosteroids (5 mg prednisone daily) suppress inflammatory markers including CRP, which is a desired therapeutic effect in autoimmune conditions. 2

  • Normalization of inflammatory markers including CRP is an important endpoint of successful immunosuppressive therapy 9
  • The combination of azathioprine and low-dose prednisone is specifically designed to maintain disease quiescence while minimizing side effects 2

Red Cell Distribution Width (RDW)

  • RDW may be elevated due to azathioprine-induced macrocytosis 8
  • The development of macrocytic changes reflects the drug's effect on DNA synthesis in rapidly dividing cells 1

Monitoring Requirements After 8 Months of Therapy

At 8 months of continuous therapy, patients should be on a reduced monitoring schedule but remain under surveillance. 2

  • Complete blood count and liver function tests should be performed at minimum every 3 months 2, 8
  • More frequent monitoring is required if any abnormalities develop or if doses are adjusted 2
  • Weekly monitoring should resume if the azathioprine dose is increased 2

Critical Clinical Considerations

Patients with TPMT or NUDT15 deficiency are at dramatically increased risk for severe, life-threatening myelosuppression. 1

  • Approximately 0.3% of European/African ancestry patients have absent TPMT activity and are at risk for fatal pancytopenia 1, 10
  • 10% have intermediate TPMT activity requiring dose reduction 2, 1
  • Among East Asian patients, 2% have two loss-of-function NUDT15 alleles and 21% have one 1
  • In patients with severe myelosuppression, evaluation for TPMT and NUDT15 deficiency should be considered 1

Steroid Effects on Blood Markers

Prednisone 5 mg daily represents a low maintenance dose that typically causes minimal direct hematologic effects but suppresses inflammatory markers. 2

  • At this dose (well below 10 mg daily), corticosteroid-related side effects are minimized 2
  • The primary effect on blood markers is suppression of inflammatory responses rather than direct hematologic toxicity 2
  • Metabolic effects (hyperglycemia, hypokalemia) may be reflected in chemistry panels 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Myelotoxicity and hepatotoxicity during azathioprine therapy.

The Netherlands journal of medicine, 2005

Research

Late-Onset Acute Liver Injury From Azathioprine.

ACG case reports journal, 2022

Guideline

Azathioprine Discontinuation Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Laboratory Monitoring for Patients on Azathioprine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Decreasing Alkaline Phosphatase (ALP) While on Azathioprine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the management options for Azothioprine (Imuran)-induced transaminitis?
What are the adverse effects of azathioprine?
What lab tests are recommended for patients on Azathioprine (Imuran)?
What monitoring is required for a patient on Azathioprine (Imuran) therapy?
Can azathioprine be continued in a patient with chronic liver damage?
What is the best approach for a patient in their 30s with severe health anxiety and panic attacks, currently taking lorazepam (benzodiazepine) 1.5 mg/day, to taper off this medication?
What is the best course of action for an elderly female patient with a history of atherosclerosis, recently diagnosed with severe muscle aches in her right shin, left thigh, and right hip after being prescribed statin (HMG-CoA reductase inhibitor) medications, which were subsequently stopped, and who has a unclear autoimmune diagnosis, normal labs showing no rhabdomyolysis, and is now seeking alternative lipid-lowering therapies?
Is a patient with iron-deficiency anemia, who has undergone iron sucrose (iron sucrose) treatment and has a current hemoglobin level of 11.1 g/dL, cleared to undergo extensive cosmetic surgery with liposuction, fat removal, and abdominoplasty?
Should a dialysis patient with End-Stage Renal Disease (ESRD) and hyperkalemia be treated?
What are the differential diagnoses for a pediatric patient presenting with alterations in carbohydrate metabolism?
Is a hernia check recommended in sports physicals, especially for individuals participating in high-intensity, contact, or heavy lifting sports?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.